按年龄、性别、治疗及疾病活动度分层的慢乙肝进展率:AASLD与EASL标准数据
该研究分析美亚多中心18338例慢性乙肝患者,按2018 AASLD及2017 EASL标准分层,估算肝硬化与肝细胞癌年发生率。结果显示即使低风险人群进展率差异大,无肝硬化者HCC年发生率0.04%–2.19%,部分年轻亚组接近或超过0.2%监测阈值。
要点
- 无肝硬化患者HCC年发生率0.04%–2.19%,部分年轻亚组接近或超过0.2%。
- 肝硬化患者HCC年发生率0.40%–8.83%,风险显著高于无肝硬化者。
- 进展率因年龄、性别、疾病活动度及治疗状态而异,需精准分层。
核心结论
- 慢性乙肝疾病进展率即使在同一风险分层内也存在很大变异,未来模型与监测推荐应基于性别、年龄、疾病活动度及治疗状态的精准进展率。
研究设计与样本
- 多中心队列研究,纳入美国6中心与亚太27中心共18338例慢性乙肝患者(8914例治疗,9424例未治疗),采用Kaplan-Meier法估算人年进展率。
主要发现
- 按AASLD标准,无肝硬化患者肝硬化年发生率0.07%–3.94%,HCC年发生率0.04%–2.19%;肝硬化患者HCC年发生率0.40%–8.83%。
- 无肝硬化患者中,男性<40岁和女性<50岁等亚组的HCC年风险接近或超过0.2%。
- 按EASL标准得到相似结果。
关键数值与推荐
- AASLD标准下无肝硬化患者HCC年发生率范围0.04%–2.19%,肝硬化患者0.40%–8.83%。
- 无肝硬化患者HCC监测年发生率阈值为0.2%,部分年轻亚组接近或超过该阈值。
临床怎么用
- 临床评估慢乙肝患者HCC监测必要性时,应结合年龄、性别、疾病活动度和治疗状态进行精准分层,而非仅凭单一阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Antiviral treatment criteria are based on disease progression risk, and hepatocellular carcinoma (HCC) surveillance recommendations for patients with chronic hepatitis B (CHB) without cirrhosis is based on an annual incidence threshold of 0.2%. However, accurate and precise disease progression estimate data are limited. Thus, we aimed to determine rates of cirrhosis and HCC development stratified by age, sex, treatment status, and disease activity based on the 2018 American Association for the Study of Liver Diseases and 2017 European Association for the Study of the Liver guidelines. METHODS: We analyzed 18,338 patients (8914 treated, 9424 untreated) from 6 centers from the United States and 27 centers from Asia-Pacific countries. The Kaplan-Meier method was used to estimate annual progression rates to cirrhosis or HCC in person-years. RESULTS: The cohort was 63% male, with a mean age of 46.19 years, with baseline cirrhosis of 14.3% and median follow up of 9.60 years. By American Association for the Study of Liver Diseases criteria, depending on age, sex, and disease activity, annual incidence rates ranged from 0.07% to 3.94% for cirrhosis, from 0.04% to 2.19% for HCC in patients without cirrhosis, and from 0.40% to 8.83% for HCC in patients with cirrhosis. Several subgroups of patients without cirrhosis including males younger than 40 years of age and females younger than 50 years of age had annual HCC risk near or exceeding 0.2%. Similar results were found using European Association for the Study of the Liver criteria. CONCLUSION: There is great variability in CHB disease progression rates even among "lower-risk" populations. Future CHB modeling studies, public health planning, and HCC surveillance recommendation should be based on more precise disease progression rates based on sex, age, and disease activity, plus treatment status.
引用
- Park J, Le AK, Tseng TC, et al. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clin Gastroenterol Hepatol. 2021. PMID: 34089852. doi:10.1016/j.cgh.2021.05.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。